ImmunoPET: A Phase 0/1 Study Characterising PD-L1 with 89Zr-Durvalumab (MEDI4736) PET/CT in Stage III NSCLC Patients Receiving Chemoradiation

被引：0

作者：

MacManus, M. ^{[1
]}

Rudd, S. ^{[2
]}

Roselt, P. ^{[1
]}

Wichmann, C. ^{[3
]}

Callahan, J. ^{[1
]}

John, T. ^{[1
]}

Scott, A. ^{[3
]}

Donnelly, P.

Hanna, G. ^{[1
]}

Hegi-Johnson, F. ^{[1
]}

机构：

[1] Peter MacCallum Canc Ctr, Melbourne, Australia

[2] Univ Melbourne, Melbourne, Australia

[3] Austin Hlth, Olivia Newton John Canc Res Inst, Melbourne, Australia

来源：

关键词：

Non-small cell lung cancer; PET Imaging; Immunotherapy;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.10-02

引用

页码：S107 / S108

页数：2